BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market. The post BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations appeared first on Investor's Business Daily.
BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market.
The post BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
